Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study
Blood Purification · 2025
DOI: 10.1159/000548158 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood Purification, 2025. Verfasst von Juan C Castillo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Care Services Soacha, Bogota DC, Colombia. Hauptthemen laut MEDLINE: Renal Dialysis, COVID-19, Kidney Failure, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Survival is a core outcome of hemodialysis (HD) therapy. Expanded hemodialysis (HDx) enabled by Theranova dialyzer increases clearance of medium-sized molecules and was reported to improve various patient-reported outcomes compared to HD using high-flux membranes, but the impact on survival is unclear. Herein, we evaluated the risk of death for HDx versus high-flux HD over a 4-year follow-up period.
Methods
This is a multicenter, retrospective cohort study in adult prevalent chronic HD at Renal Care Services – Colombia starting between September 1, 2017, and November 30, 2017, with follow-up for up to 4 years. The sociodemographic and clinical characteristics of all patients were summarized descriptively. The Fine-Gray subdistribution hazard model was employed to evaluate the sub-hazard ratio of factors associated with time to death from causes other than COVID-19; death attributable to COVID-19 was considered as a competing risk. Sensitivity analyses included Cox proportional hazards model, extended Cox regression, and Cox regression after adjusting for imbalances between cohorts using the inverse probability of treatment weighting method.
Results
We evaluated 1,092 patients, 559 in HDx cohort and 533 in high-flux HD cohort; the mean age 61 years; 42% had diabetes, and 19% had cardiovascular disease. HDx using the Theranova dialyzer had a protective effect with reduction of mortality risk when controlling for confounding variables, SHR = 0.79 [95% CI: 0.62–0.98, p = 0.035]. Sensitivity analyses also showed a statistically significant beneficial effect of HDx versus high-flux HD.
Conclusions
HDx enabled by Theranova dialyzer was associated with an approximately 21% reduction in mortality risk compared to treatment with high-flux HD in patients followed for up to 4 years. It would be desirable for these very promising results to be corroborated by a randomized controlled trial, with sufficient follow-up time to investigate the effect described in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Care Services Soacha, Bogota DC, Colombia.
- Renal Care Services Colombia, Bucaramanga, Colombia.
- Vantive, Deerfield, Illinois, USA.
- Vantive, Zurich, Switzerland.
- Clinical Research Institute, Faculty of Medicine, National University of Colombia, Bogota DC, Colombia.
- Faculty of Medicine, Sabana University, Bogota DC, Colombia.
Zitieren
APA
Castillo, J. C., Vesga, J., Rivera, A., Rutherford, P., Sanchez, R., Oliveros, H., Lindholm, B., & Sanabria, M. (2025). Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study. Blood Purification. https://doi.org/10.1159/000548158
Vancouver
Castillo JC, Vesga J, Rivera A, Rutherford P, Sanchez R, Oliveros H, et al. Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study. Blood Purification. 2025. doi:10.1159/000548158
BibTeX
@article{Castillo2025,
author = {Castillo, Juan C and Vesga, Jasmin and Rivera, Angela and Rutherford, Peter and Sanchez, Ricardo and Oliveros, Henry and Lindholm, Bengt and Sanabria, Mauricio},
title = {Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study},
journal = {Blood Purification},
year = {2025},
doi = {10.1159/000548158}
}
EUVIMED